MGS opens new drug delivery device manufacturing facility
The Richfield, Wisconsin manufacturing site is the 12th global facility for MGS. [Photo courtesy of MGS]
MGS has brought a 300,000 square foot drug delivery device manufacturing facility online in Richfield, Wisconsin.
The medtech CDMO’s newest facility expands U.S. production capacity as demand for complex combination products strains available cleanroom capacity. MGS said it developed the facility to support an unnamed global pharmaceutical company’s drug delivery platform.
The site has 140,000 square feet of ISO Class 8 cleanroom space dedicated to high volume manufacturing, automation and assembly of complex drug delivery devices. The facility is designed to handle hundreds of millions of sub assemblies annually.
The scale reflects surging demand for injectable GLP-1 therapies, where autoinjectors and prefilled pen devices have become manufacturing bottlenecks as semaglutide and tirzepatide prescriptions continue to outpace supply. FDA approved a record number of combination products in recent years, and the 505(b)(2) pathway has made device-drug combos more attractive.
Free download: MassDevice’s Diabetes Technology Innovations Special Report ranks the world’s largest diabetes technology companies and more
From initial discussions to shipped parts, the project moved from concept to operation in 22 months, according to MGS.
“From day one, every decision was guided by our customer’s needs and the patients they serve,” MGS Sales and Marketing SVP Bob Bordignon said in a news release. “This facility is proof of what’s possible when aligned expertise and a shared vision come together to accelerate life-changing therapies. Our agile structure and financial strength enabled the speed, investment and coordination required to bring this complex project to life on an ambitious timeline.”
The MGS manufacturing facility in Richfield, Wisconsin, has more than 100 injection molding machines. [Photo courtesy of MGS]
Phase one of the buildout includes more than 100 injection molding machines along with custom automation systems and high efficiency automated assembly lines. A planned second phase will double production capacity to accommodate long term product growth.
MGS expects to add 300 jobs across engineering, automation, production, quality and mold maintenance at the facility, with full staffing anticipated by early 2027. Roles range from automation technicians and process engineers to metrology and molding specialists. The site will operate on a rotating schedule designed to provide workforce flexibility while maintaining continuous production.
The Richfield expansion brings MGS to 12 facilities globally. MGS is a vertically integrated CDMO spanning early stage design and development, advanced tooling, custom automation and precision medical manufacturing.
This article was originally published at our Pharmaceutical Processing World website.
No Byline Policy
Editorial Guidelines
Corrections Policy
Source